Pulmonary Eosinophilia

Vaccines and Antiviral Agents
Differential Role of Gamma Interferon in Inhibiting Pulmonary Eosinophilia and Exacerbating Systemic Disease in Fusion Protein-Immunized Mice Undergoing Challenge Infection with Respiratory Syncytial Virus
Elaine M. Castilow, Matthew R. Olson, David K. Meyerholz, Steven M. Varga
Pathogenesis and Immunity | Spotlight
C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression
Guillermina A. Melendi, Scott J. Hoffman, Ruth A. Karron, Pablo M. Irusta, Federico R. Laham, Alison Humbles, Brian Schofield, Chien-Hsiung Pan, Richard Rabold, Bhagvanji Thumar, Adeep Thumar, Norma P. Gerard, Wayne Mitzner, Scott R. Barnum, Craig Gerard, Steven R. Kleeberger, Fernando P. Polack
Pathogenesis and Immunity
Vβ14⁺ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV
Teresa R. Johnson, Steven M. Varga, Thomas J. Braciale, Barney S. Graham
Pathogenesis and Immunity
Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV
Teresa R. Johnson, Michael N. Teng, Peter L. Collins, Barney S. Graham
Pathogenesis and Immunity
Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P
Lia M. Haynes, Les P. Jones, Albert Barskey, Larry J. Anderson, Ralph A. Tripp
Pathogenesis and Immunity
Priming with a Secreted Form of the Fusion Protein of Respiratory Syncytial Virus (RSV) Promotes Interleukin-4 (IL-4) and IL-5 Production but Not Pulmonary Eosinophilia following RSV Challenge
Gary P. Bembridge, Juan A. Lopez, Regla Bustos, Jose A. Melero, Roy Cook, Helen Mason, Geraldine Taylor